Junk Bonds Are Quietly Flashing Yellow, and Equity Investors Should Notice
High-yield bond yields have jumped to 8.1%, with stress concentrated in the weakest credits. Here is why equity investors should watch the signal.
THE INVESTOR’S PERSPECTIVE
Ideas, analysis, and opportunities across the world of investing.
High-yield bond yields have jumped to 8.1%, with stress concentrated in the weakest credits. Here is why equity investors should watch the signal.
Delta cut its 2026 profit outlook by about 24% as jet fuel nearly doubled, yet revenue grew 21% and premium sales surged 18%. The real test for patient investors: is the premium-cabin mix a durable moat, or just a good cycle?
Avery Dennison's 19.4% EPS growth looks impressive, but half the quarter's gain came from inventory stocking that's set to unwind. A 15-year dividend growth streak and 16x earnings multiple still make the long-term case interesting.
PepsiCo sits near a 52-week low with a 4.7% yield, even as its 54-year dividend streak stays intact. Elliott Management's $4B activist stake and Thursday's earnings will test if the turnaround funds the raise.
Occidental converts 45% of revenue into profit, with earnings growing ten times faster than revenue last quarter. But $7 billion a year plowed back into drilling raises the question of whether that moat is widening or just holding the line.
Wells Fargo is 2026's worst-performing big bank, down 14%, but Morgan Stanley just called it a top pick with 27% upside. Trading at 1.5x 2027 tangible book value, 18 of 26 analysts already rate it a buy.
Berkshire raised its Lennar stake to 11.2% ($2.1B) this week as Morgan Stanley initiated coverage with an underweight rating and 19% downside target. The multi-quarter build reveals a long-term bet on housing's recovery that contrasts with Wall Street's near-term rate fears.
McDonald's $8.5B 'Next' turnaround sent shares to a 2022 low, but a sub-19 P/E and 3.2% yield on a 49-year dividend grower looks cheap for patient investors. The real test: can new leadership close a five-year performance gap versus Yum and Restaurant Brands?
Nike's stock is down 40%+ in 2026, but its $2.5B 'Pace' restructuring and resilient North America margins tell a longer-term story. The real test for patient investors: does the savings plan show up in margin expansion by 2031.
Micron crushed earnings with 4x revenue growth and raised guidance, yet shares barely moved after a 273% YTD rally. The real question for long-term holders: will $250B in HBM capex convert into durable returns, or was this priced to perfection?
Moderna shares have rocketed 223% since mid-August on a single piece of clinical trial news — and Citi just told investors it's time to
TotalEnergies just did something dividend investors should pay close attention to: it raised its buyback program AND its production growth targets at the same time, funded